CHL1 and A375 melanoma cells were subjected to treatment with 500 nM of the PRMT5 inhibitor GSK3326595 for 72 hours or with 1 μM of the CDK4/6 inhibitor palbociclib for either 72 hours or 6 days. This evidence concerns the gene PRMT5 and melanoma.